Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study
Medicina · 07.03.2026 · 62 (3) · 499
DOI: 10.3390/medicina62030499 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 07.03.2026. Verfasst von Svetoslav Stoev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria. Hauptthemen laut MEDLINE: Gastrointestinal Diseases, Trimebutine. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the European Union NextGenerationEU procedure "Creating a network of research universities", European Union NextGenerationEU.
Abstract (Originalsprache)
Background and Objectives: This prospective, non-interventional, multicenter study aims to assess the therapeutic effectiveness of trimebutine maleate in patients with functional gastrointestinal disorders (FGIDs) by patient-reported outcomes. Materials and Methods: The study encompassed 2501 patients from 50 clinical sites diagnosed with irritable bowel syndrome, functional dyspepsia, or other functional gastrointestinal diseases. A validated questionnaire, an adapted version of the Izumo scale, was employed for self-assessment of symptoms and quality of life related to gastrointestinal issues.
Results
The findings indicate a significant decrease in symptom severity, encompassing epigastric pain, dyspeptic symptoms, and defecation difficulties, as early as the second visit, with mean pain scores declining from 2.65 to 0.46 (p < 0.001).
Conclusions
The data validate trimebutine’s profile as a well-tolerated and efficacious therapy for patients with IBS in real-world clinical practice in Bulgaria. The findings endorse the prospective inclusion of trimebutine as a treatment option in forthcoming clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria.
- Research Institute, Medical University-Pleven, 5800 Pleven, Bulgaria.
- Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynecology Dr. Shterev, 1330 Sofia, Bulgaria.
- Department of Health Management and Health Economics, Faculty of Public Health, Medical University of Sofia, 1000 Sofia, Bulgaria.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
- Department "Organization and Economics of Pharmacy", Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.
ORCID-Profile: Svetoslav Stoev, Vesselina Yanachkova, Elina Petkova-Gueorguieva, Stanislav Gueorguiev, Violeta Getova-Kolarova, Hristina Lebanova
Förderung
- the European Union NextGenerationEU procedure "Creating a network of research universities"
- European Union NextGenerationEU
Zitieren
APA
Stoev, S., Yanachkova, V., Petkova-Gueorguieva, E., Gueorguiev, S., Getova-Kolarova, V., Lebanova, H., & Koynarski, V. (2026). Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study. Medicina, 62(3), 499. https://doi.org/10.3390/medicina62030499
Vancouver
Stoev S, Yanachkova V, Petkova-Gueorguieva E, Gueorguiev S, Getova-Kolarova V, Lebanova H, et al. Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study. Medicina. 2026;62(3):499. doi:10.3390/medicina62030499
BibTeX
@article{Stoev2026,
author = {Stoev, Svetoslav and Yanachkova, Vesselina and Petkova-Gueorguieva, Elina and Gueorguiev, Stanislav and Getova-Kolarova, Violeta and Lebanova, Hristina and Koynarski, Vasil},
title = {Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study},
journal = {Medicina},
year = {2026},
volume = {62},
number = {3},
pages = {499},
doi = {10.3390/medicina62030499}
}
EUVIMED